Author: Brenda Marie Rivers|| Date Published: April 17, 2020
The Biomedical Advanced Research and Development Authority has awarded Moderna a potential $483M contract to further develop a vaccine against to the novel coronavirus SARS-CoV-2.
Moderna said Thursday it will use the funds to advance the biotechnology firm’s messenger RNA-based vaccine candidate to the Food and Drug Administration’s licensure process.
A Phase 1 study, led by the National Institutes of Health, began last month and will provide data to support Phase 2 work that is scheduled to begin in the second quarter of 2020.
The Cambridge, Mass.-based company expects Phase 3 assessments of the mRNA-1273 vaccine to commence this fall and aims to conduct large-scale manufacturing efforts later this year
Stephane Bancel, CEO of Moderna, said the HHS supports collective efforts to supply millions of doses each month and an even larger amount over the next year.
The company seeks to grow its U.S. workforce size by 150 personnel and enroll new volunteers for the vaccine testing phase on an ongoing basis.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
